Grant: Discovery Grants Program - Individual
University of Saskatchewan
$32,000.00
APOBEC3 DNA deaminases: Biochemical basis of hypermutation
FY 2014-15
Summary
As part of human innate immunity, the APOBEC3 family of enzymes purposefully deaminate numerous cytosines to uracils in the single-stranded DNA replication intermediate of HIV, if the virion lacks the protein Vif. Subsequent replication of the DNA intermediate into double-stranded DNA creates a guanine to adenine hypermutated and likely inactivated provirus. APOBEC3 enzymes could be a potent therapeutic route for HIV treatment if their suppression by Vif can be alleviated. However, if aberrant APOBEC3-catalyzed deaminations were to occur in host cell DNA, likely during transcription, then induced mutations may contribute to cell transformation and cancer. As a result, it is important to have a thorough understanding of APOBEC3 biochemistry in order to anticipate both the positive and negative consequences of their use in HIV therapeutics. The APOBEC3 family is composed of seven enzymes with similar function, APOBEC3A, 3B, 3C, 3DE, 3F, 3G and 3H. Currently the only detailed biochemical knowledge is from studies on APOBEC3G. My research program aims to biochemically characterize all APOBEC3 enzymes to determine their affinity for DNA, deamination activity, mechanisms used to scan for deamination targets, mode of interacting with DNA, and catalytic rate. Based on differences in overall enzyme charge, which affects interactions with the DNA substrate, I expect to find that members will have a diverse repertoire of characteristics. The next set of experiments will determine the characteristics that are most advantageous for deamination in complex in vitro systems that model deamination within the cell during HIV replication and during transcription of DNA. All together, the proposed research will provide the much needed comparative biochemical data to establish models for how the APOBEC3 enzyme family interacts with DNA to scan for deamination targets. Establishing the biochemical basis of deamination in the APOBEC3 family will further our molecular understanding of viral immunity and determine the potential of APOBEC3 enzymes to contribute to cell transformation if deamination is uncontrolled.
Program
Discovery Grants Program - Individual
Recipient
Location
Saskatchewan, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
386090-2010
Name nom
Chelico, Linda
Department département
Microbiology and Immunology
Organization id
16
Institution établissement
University of Saskatchewan
Province en
Saskatchewan
Province fr
Saskatchewan
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2014
Competition year année de concours
2010
Award amount
32000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1501
Committee name en
Genes, Cells and Molecules
Committee name fr
Gènes, cellules et molécules
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
5400
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Biochemistry
Research subject fr
Biochimie
Partie
5
Nb partie
5
Application title
APOBEC3 DNA deaminases: Biochemical basis of hypermutation
Keyword
NSERC
Application summary
As part of human innate immunity, the APOBEC3 family of enzymes purposefully deaminate numerous cytosines to uracils in the single-stranded DNA replication intermediate of HIV, if the virion lacks the protein Vif. Subsequent replication of the DNA intermediate into double-stranded DNA creates a guanine to adenine hypermutated and likely inactivated provirus. APOBEC3 enzymes could be a potent therapeutic route for HIV treatment if their suppression by Vif can be alleviated. However, if aberrant APOBEC3-catalyzed deaminations were to occur in host cell DNA, likely during transcription, then induced mutations may contribute to cell transformation and cancer. As a result, it is important to have a thorough understanding of APOBEC3 biochemistry in order to anticipate both the positive and negative consequences of their use in HIV therapeutics. The APOBEC3 family is composed of seven enzymes with similar function, APOBEC3A, 3B, 3C, 3DE, 3F, 3G and 3H. Currently the only detailed biochemical knowledge is from studies on APOBEC3G. My research program aims to biochemically characterize all APOBEC3 enzymes to determine their affinity for DNA, deamination activity, mechanisms used to scan for deamination targets, mode of interacting with DNA, and catalytic rate. Based on differences in overall enzyme charge, which affects interactions with the DNA substrate, I expect to find that members will have a diverse repertoire of characteristics. The next set of experiments will determine the characteristics that are most advantageous for deamination in complex in vitro systems that model deamination within the cell during HIV replication and during transcription of DNA. All together, the proposed research will provide the much needed comparative biochemical data to establish models for how the APOBEC3 enzyme family interacts with DNA to scan for deamination targets. Establishing the biochemical basis of deamination in the APOBEC3 family will further our molecular understanding of viral immunity and determine the potential of APOBEC3 enzymes to contribute to cell transformation if deamination is uncontrolled.